急诊治疗126例重症心力衰竭的临床效果探究

Probe of Clinical Results Emergency Treatment of 126 Cases of Severe Heart Failure

目的 探讨急诊治疗重症心力衰竭的临床疗效.方法 随机抽取急诊内科收治的重症心力衰竭患者126例做为研究对象,按随机双盲法分为观察组与对照组各63例,对照组行常规对症治疗,观察组在对照组治疗的基础上给予美托洛尔联合厄贝沙坦氢氯噻嗪治疗,两组疗程均为1～2w,治疗结束后,对两组的临床疗效进行比较,同时对两组治疗前后的舒张压、心率、左心室射血分数、心功能分级进行比较.结果 治疗后,观察组显效率与总有效率分别为41.26％(26例)、90.47％(57例),明显高于对照组的23.80％(15例)、71.42％(45例),差异有统计学意义(P＜0.05);观察组舒张压、心率、左心室射血分数、心功能分级等各项指标明显高于对照组,差异有统计学意义(P＜0.05).结论 治疗急诊内科重症心力衰竭时,在常规对症治疗的基础上加入美托洛尔联合厄贝沙坦氢氯噻嗪,能有效提高临床疗效,效果显著,值得临床推广应用.

Objective To study and discuss the clinical effect of emergency treatment of severe heart failure.Methods During December 2012 to December 2013 in our hospital randomly selected patients with severe heart failure admitted to the emergency internal medicine, 126 cases as the object of study, a randomized double blind method were randomly divided into observation group and control group 63 cases, control group patients, regular treatment was applied to the observation group, 63 cases of patients, to give the treatment of metoprolol and irbesartan hydrochlorothiazide based on the treatment in control group, two groups of patients with treatment for 1~2 weeks, after the end of treatment, compared the clinical efficacy of the two groups, and to compare the two groups of patients before and after the patient's blood pressure, heart rate,left ventricular ejection fraction, cardiac functional grading.Result After treatment, the observation group of significant efficiency and total effective rate were 41.26%(26 cases), 90.47%(57 cases),significantly higher than the control group 23.80%(15 cases), 71.42%(45 cases), there were statistically significant(P<0.05); observation group blood pressure, heart rate, left ventricular ejection fraction, cardiac functional grading indexes were significantly higher than the control group, there were statistically significant(P<0.05).Conclusion Treatment of severe heart failure patients in emergency internal medicine, using the conventional treatment based on symptomatic treatment of adding to the treatment of metoprolol and irbesartan hydrochlorothiazide, can effectively improve the clinical efficacy of such patients, significant effect, worthy of promotion in clinical and should be used.